iBio (IBIO) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

iBio (IBIO) overview

iBio (IBIO) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -35.1m; the year-end share price was 1.75 USD and market capitalisation was USD 97.5m. iBio is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get iBio's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 85.7mFY 2026
Share price1.75 USDFY 2026 year end
RevenueUSD 0.1mFY 2026
Operating profitUSD -35.1mFY 2026
Net earningsUSD -33.0mFY 2026
Market capitalisationUSD 97.5mFY 2026 year end

About iBio

iBio is a clinical-stage biotechnology company using artificial intelligence and machine learning to develop antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases. Its pipeline includes a clinical-stage long-acting myostatin antibody and preclinical candidates, including antibodies targeting Activin E and a myostatin–Activin A bispecific antibody. The company conducts discovery and development work at its research laboratory in San Diego.

Generate the iBio report

iBio is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for iBio and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on iBio

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.